Advertisement
TRDA 外匯新聞
Entrada Therapeutics Says FDA Declines To Lift Clinical Hold On ENTR-601-44 IND Application
Biopharmaceutical company Entrada Therapeutics, Inc. (TRDA) announced Wednesday the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
RTTNews
|
569天前
